Want to see ETON full AI Analyst Report?
Total Valuation
Eton Pharmaceuticals has a market cap or net worth of $1.71B. The enterprise value is $1.19K.
Market Cap$1.71B
Enterprise Value$1.19K
Share Statistics
Eton Pharmaceuticals has 28,583,136 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding28,583,136
Owned by Insiders14.96%
Owned by Institutions35.34%
Financial Efficiency
Eton Pharmaceuticals’s return on equity (ROE) is -0.18 and return on invested capital (ROIC) is 0.12%.
Return on Equity (ROE)-0.18
Return on Assets (ROA)-0.05
Return on Invested Capital (ROIC)0.12%
Return on Capital Employed (ROCE)<0.01
Revenue Per Employee1.82M
Profits Per Employee-104.57K
Employee Count44
Asset Turnover0.87
Inventory Turnover2.41
Valuation Ratios
The current PE Ratio of Eton Pharmaceuticals is 125.7. Eton Pharmaceuticals’s PEG ratio is -7.46.
PE Ratio125.7
PS Ratio5.69
PB Ratio17.40
Price to Fair Value17.40
Price to FCF44.65
Price to Operating Cash Flow106.75
PEG Ratio-7.46
Income Statement
In the last 12 months, Eton Pharmaceuticals had revenue of 79.95M and earned -4.60M in profits. Earnings per share was -0.17.
Revenue79.95M
Gross Profit42.74M
Operating Income72.00K
Pretax Income-4.56M
Net Income-4.60M
EBITDA4.27M
Earnings Per Share (EPS)-0.17
Cash Flow
In the last 12 months, operating cash flow was 15.13M and capital expenditures -403.00K, giving a free cash flow of 14.73M billion.
Operating Cash Flow15.13M
Free Cash Flow14.73M
Free Cash Flow per Share0.52
Dividends & Yields
Eton Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.61
52-Week Price Change228.74%
50-Day Moving Average47.74
200-Day Moving Average28.28
Relative Strength Index (RSI)56.85
Average Volume (3m)634.37K
Important Dates
Eton Pharmaceuticals upcoming earnings date is Nov 5, 2026, TBA (Confirmed).
Last Earnings DateAug 13, 2026
Next Earnings DateNov 5, 2026
Ex-Dividend Date―
Financial Position
Eton Pharmaceuticals as a current ratio of 1.57, with Debt / Equity ratio of 62.22%
Current Ratio1.57
Quick Ratio1.17
Debt to Market Cap0.07
Net Debt to EBITDA1.19
Interest Coverage Ratio0.02
Taxes
In the past 12 months, Eton Pharmaceuticals has paid 43.00K in taxes.
Income Tax43.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Eton Pharmaceuticals EV to EBITDA ratio is 107.83, with an EV/FCF ratio of 45.15.
EV to Sales5.75
EV to EBITDA107.83
EV to Free Cash Flow45.15
EV to Operating Cash Flow43.72
Balance Sheet
Eton Pharmaceuticals has $26.84M in cash and marketable securities with $28.99M in debt, giving a net cash position of -$2.14M billion.
Cash & Marketable Securities$26.84M
Total Debt$28.99M
Net Cash-$2.14M
Net Cash Per Share-$0.07
Tangible Book Value Per Share-$0.18
Margins
Gross margin is 57.87%, with operating margin of 0.09%, and net profit margin of -5.75%.
Gross Margin57.87%
Operating Margin0.09%
Pretax Margin-5.70%
Net Profit Margin-5.75%
EBITDA Margin5.34%
EBIT Margin0.28%
Analyst Forecast
The average price target for Eton Pharmaceuticals is $61.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$61.50
Price Target Upside-2.46% Downside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast81.49%
EPS Growth Forecast―